Is ANTADYS registered in Rwanda?

ANTADYS is recorded with registration status “Registered” in Rwanda, registration number Rwanda FDA-HMP-MA-1611, based on Rwanda FDA data.

Who manufactures ANTADYS?

ANTADYS is manufactured by Laboratoires Macors.

What is the active ingredient in ANTADYS?

ANTADYS contains Flurbiprofen 100 mg capsules, dosage form Film-coated capsules,.

Registered Rwanda · Rwanda FDA

ANTADYS

Flurbiprofen 100 mg capsules

Rwanda FDA-HMP-MA-1611 Film-coated capsules, 100 mg musculo-skeletal system INN generic

What it does

Flurbiprofen is a non-steroidal anti-inflammatory drug (NSAID) used to relieve pain and reduce inflammation.

Commonly used for: pain relief, swelling (inflammation), arthritis, muscle pain

Registration & product details

Registration no.

Rwanda FDA-HMP-MA-1611

Registration date

17/08/2024

Expiry date

16/08/2029

Status

Registered

Active ingredient

Flurbiprofen 100 mg capsules

Dosage form

Film-coated capsules,

Strength

100 mg

Pack size

15 or 60 Capsuls

Therapeutic class

ATC class (WHO)

M01AE - Propionic acid derivatives

Drug group

MUSCULO-SKELETAL SYSTEM

RxNorm RxCUI

4502

Manufacturer / MAH

Laboratoires Macors

Applicant / LTR

LABORATOIRE B&O PHARM

Country of origin

FRANCE

Manufacturer location

22 Rue des Caillottes, 89000 Auxerre, France

Source: Rwanda Food and Drugs Authority · fetched 2026-03-11 22:07:05 · updated 2026-09-17 02:30:43

Drug Interactions

Check interactions

Pharmacodynamic Warnings

Flurbiprofen appears in TABLE 2: Drugs that cause nephrotoxicity

Flurbiprofen appears in TABLE 4: Drugs with antiplatelet effects

Flurbiprofen appears in TABLE 16: Drugs that increase serum potassium

Flurbiprofen appears in TABLE 18: Drugs that cause hyponatraemia

Severe (1)

Mifamurtide - decreases efficacy

NSAIDs(high-dose)arepredictedtodecreasetheefficacyof mifamurtide.Avoid.rTheoretical

Severe Theoretical

Moderate (5)

Antiarrhythmics - increases exposure

NSAIDs (celecoxib) are predicted to increase the exposure to antiarrhythmics (flecainide, propafenone). Monitor and adjust dose.

Moderate Theoretical

Cladribine - increases exposure

NSAIDs(sulindac)mightincreasetheexposuretocladribine. Avoidoradjustdose.oTheoretical

Moderate Theoretical

Flecainide - increases exposure

NSAIDs (celecoxib) are predicted to increase the exposure to antiarrhythmics (flecainide, propafenone). Monitor and adjust dose.

Moderate Theoretical

Pemetrexed - increases exposure

NSAIDs are predicted to increase the exposure to pemetrexed. Use with caution or avoid. Also see TABLE 2 p. 1517

Moderate Theoretical

Propafenone - increases exposure

NSAIDs (celecoxib) are predicted to increase the exposure to antiarrhythmics (flecainide, propafenone). Monitor and adjust dose.

Moderate Theoretical

Unknown (8)

Alendronate - increases risk of gastrointestinal irritation

NSAIDs are predicted to increase the risk of gastrointestinal irritation when given with bisphosphonates (alendronate, ibandronate).

Unknown Study

Bisphosphonates - increases risk of gastrointestinal irritation

NSAIDs are predicted to increase the risk of gastrointestinal irritation when given with bisphosphonates (alendronate, ibandronate).

Unknown Study

Bisphosphonates - increases risk of renal impairment

NSAIDs are predicted to increase the risk of renal impairment when given with bisphosphonates (clodronate).

Unknown Study

Clodronate - increases risk of renal impairment

NSAIDs are predicted to increase the risk of renal impairment when given with clodronate.

Unknown Study

Deferasirox - increases risk of gastrointestinal bleeding

NSAIDs are predicted to increase the risk of gastrointestinal bleeding when given with deferasirox.

Unknown Theoretical

Deferiprone - increases exposure

NSAIDs(diclofenac)arepredictedtoincreasetheexposureto deferiprone.oTheoretical

Unknown Theoretical

Ibandronate - increases risk of gastrointestinal irritation

NSAIDs are predicted to increase the risk of gastrointestinal irritation when given with bisphosphonates (alendronate, ibandronate).

Unknown Study

Ironchelators - increases risk of gastrointestinal bleeding

NSAIDs are predicted to increase the risk of gastrointestinal bleeding when given with iron chelators (deferasirox).

Unknown Theoretical

Data from BNF 85 (British National Formulary). This is not a substitute for professional medical advice. Matched via: class

Disclaimer: This information is sourced from Rwanda Food and Drugs Authority (Rwanda). Always consult a qualified healthcare professional before using any medication.

About this medicine

Flurbiprofen is a non-steroidal anti-inflammatory drug (NSAID) used to relieve pain and reduce inflammation.

What it treats

pain relief
swelling (inflammation)
arthritis
muscle pain

How it works

Flurbiprofen works by blocking substances in the body that cause pain and inflammation.

Who it's for

Flurbiprofen is suitable for adults and children over a certain age for treating pain and inflammation.

Drug class

NSAIDs

Cautions

• Be careful if you are taking medications that can harm the kidneys.
• Use with caution if you are on drugs that affect blood clotting.
• Avoid if you are taking medications that can raise potassium levels in the blood.
• Take care if you have medications that can lower sodium levels.

AI-assisted summary grounded in BNF data - general information only, not medical advice. Always confirm with your pharmacist or doctor.

Clinical monograph: Flurbiprofen

BNF-referenced

Flurbiprofen is a nonsteroidal anti-inflammatory drug (NSAID) belonging to the propionic acid class. It is primarily used for its analgesic, anti-inflammatory, and antipyretic properties. Flurbiprofen is indicated for the treatment of pain and inflammation associated with various musculoskeletal disorders, including rheumatic diseases, dysmenorrhoea, and postoperative pain. It is recognized for its potency in inhibiting the synthesis of prostaglandins, which are mediators of pain and inflammation.

Indications

Pain and inflammation in musculoskeletal disorders
Rheumatic diseases
Dysmenorrhoea
Postoperative pain
Mild to moderate pain

Dosage

Children: Refer to the BNF for Children for specific paediatric dosing information

Adults: Refer to the BNF for specific dosing information. Generally, flurbiprofen is administered orally or topically depending on the formulation and condition being treated.

Mechanism of action

Flurbiprofen exerts its anti-inflammatory effects through reversible inhibition of cyclooxygenase (COX) enzymes, which are crucial for the conversion of arachidonic acid to prostaglandins. By inhibiting both COX-1 and COX-2, flurbiprofen decreases the synthesis of prostaglandins involved in the inflammatory response, thereby alleviating pain, swelling, and fever.

Pharmacodynamics

As a nonsteroidal anti-inflammatory agent, flurbiprofen shares structural and pharmacological similarities with other NSAIDs such as ibuprofen and ketoprofen. The drug exhibits significant anti-inflammatory, analgesic, and antipyretic activities. Its therapeutic efficacy is attributed primarily to the S-enantiomer, which demonstrates predominant anti-inflammatory effects, while both enantiomers contribute to its analgesic properties.

Pharmacokinetics

Flurbiprofen is absorbed well from the gastrointestinal tract, with peak plasma concentrations occurring within 1 to 2 hours after oral administration. It is extensively metabolized in the liver, primarily through glucuronidation, and is excreted mainly in the urine. The drug has a half-life of approximately 3 to 6 hours. The pharmacokinetics may vary in individuals with renal impairment, necessitating caution in dosing for this population.

Contra-indications

Hypersensitivity to flurbiprofen or any of its excipients
History of gastrointestinal bleeding or ulceration
Severe renal impairment
Active peptic ulcer disease
History of allergic reactions to NSAIDs

Adverse effects

Gastrointestinal disturbances (nausea, vomiting, diarrhea, constipation)
Headache
Dizziness
Drowsiness
Rash or allergic reactions
Renal impairment
Increased risk of cardiovascular events
Photosensitivity

Interactions

Increased risk of gastrointestinal bleeding with anticoagulants
May reduce the efficacy of antihypertensive medications
Increased risk of nephrotoxicity with other nephrotoxic agents
Potentially increased effects of other NSAIDs

Precautions

Caution in patients with renal impairment, heart failure, or gastrointestinal disorders
Use with caution in elderly patients due to increased risk of adverse effects
Monitor for signs of gastrointestinal bleeding
Consider alternative analgesics in patients with a history of cardiovascular disease

Pregnancy

Flurbiprofen should be avoided, especially in the third trimester due to the risk of fetal cardiovascular effects. Consult healthcare providers for alternatives.

Breast-feeding

Use with caution; flurbiprofen is excreted in breast milk. Monitor infant for any adverse effects.

Storage

Store in a cool, dry place, away from direct sunlight. Keep out of reach of children.

Formulations

Tablets
Topical gel
Eye drops

BNF 85 (British National Formulary) p.1275 BNF 85 (British National Formulary) p.1312 BNF 85 (British National Formulary) p.1353 BNF for Children 2019-2020 p.700 BNF for Children 2019-2020 p.727 BNF for Children 2019-2020 p.753 PubChem / pathway

AI-synthesized from BNF references - general information only, not a substitute for professional medical advice or the current BNF. Verify doses with a pharmacist.

Molecular reference: Flurbiprofen

PubChem CID 3394

Molecular formula: C15H13FO2

Mechanism of action

Similar to other NSAIAs, the anti-inflammatory effect of flurbiprofen occurs via reversible inhibition of cyclooxygenase (COX), the enzyme responsible for the conversion of arachidonic acid to prostaglandin G2 (PGG2) and PGG2 to prostaglandin H2 (PGH2) in the prostaglandin synthesis pathway. This effectively decreases the concentration of prostaglandins involved in inflammation, pain, swelling and fever. Flurbiprofen is a non-selective COX inhibitor and inhibits the activity of both COX-1 and -2. It is also one of the most potent NSAIAs in terms of prostaglandin inhibitory activity.

Pharmacodynamics

Flurbiprofen, a nonsteroidal anti-inflammatory agent (NSAIA) of the propionic acid class, is structually and pharmacologically related to fenoprofen, ibuprofen, and ketoprofen, and has similar pharmacological actions to other prototypica NSAIAs. Flurbiprofen exhibits antiinflammatory, analgesic, and antipyretic activities. The commercially available flurbiprofen is a racemic mixture of (+)S- and (-) R-enantiomers. The S-enantiomer appears to possess most of the anti-inflammatory, while both enantiomers may possess analgesic activity.